Your browser doesn't support javascript.
loading
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.
Denton, Christopher C; Vodala, Sadanand; Veluswamy, Saranya; Hofstra, Thomas C; Coates, Thomas D; Wood, John C.
Afiliación
  • Denton CC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
  • Vodala S; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.
  • Veluswamy S; Bristol Myers Squibb, Summit, NJ.
  • Hofstra TC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
  • Coates TD; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.
  • Wood JC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
Blood ; 142(22): 1932-1934, 2023 11 30.
Article en En | MEDLINE | ID: mdl-37704579
Splenic iron decreased whereas liver iron was stable during luspatercept therapy in some individuals with thalassemia. This suggests a reduction of ineffective erythropoiesis changes the organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron content. This article describes data from subjects enrolled in BELIEVE (NCT02604433) and BEYOND (NCT03342404).
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Talasemia beta / Hierro Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Talasemia beta / Hierro Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article